MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.270
+0.035
+2.83%
After Hours: 1.215 -0.055 -4.33% 13:47 11/27 EST
OPEN
1.220
PREV CLOSE
1.235
HIGH
1.270
LOW
1.217
VOLUME
93.84K
TURNOVER
--
52 WEEK HIGH
1.640
52 WEEK LOW
0.9000
MARKET CAP
60.83M
P/E (TTM)
-2.2466
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vascular Biogenics Ltd. (NASDAQ:VBLT) Analysts Just Slashed Next Year's Revenue Estimates By 16%
The latest analyst coverage could presage a bad day for Vascular Biogenics Ltd. (NASDAQ:VBLT), with the analysts...
Simply Wall St. · 11/18 05:31
How Much Is Vascular Biogenics Ltd. (NASDAQ:VBLT) Paying Its CEO?
This article will reflect on the compensation paid to Dror Harats who has served as CEO of Vascular Biogenics Ltd...
Simply Wall St. · 11/16 16:50
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/16 13:25
Vascular Biogenics Q3 EPS $(0.12) Beats $(0.13) Estimate, Sales $193.00K Beat $170.00K Estimate
Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 14.29 percent increase over losses of $(0.14) per share from
Benzinga · 11/16 12:05
VBL Therapeutics EPS beats by $0.01, misses on revenue
VBL Therapeutics (VBLT): Q3 GAAP EPS of -$0.12 beats by $0.01.Revenue of $0.19M (+137.5% Y/Y) misses by $0.01M.Press Release
Seekingalpha · 11/16 12:04
Vascular Biogenics Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Vascular Biogenics Ltd.
ACCESSWIRE · 11/16 11:30
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15 15:14
Earnings Outlook For Vascular Biogenics
Vascular Biogenics (NASDAQ: VBLT) announces its next round of earnings this Monday, November 16. Here is Benzinga's everything-that-matters guide for this Monday's Q3 earnings announcement.Net Income, Earnings, And Earnings Per Share Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.Earnings And Revenue Sell-side analysts are expecting Vascular Biogenics's loss per share to be near $0.13 on sales of $170.00 thousand. In the same quarter last year, Vascular Biogenics announced EPS of $0.14 on revenue of $79.00 thousand.What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.View more earnings on VBLTIf the company were to report earnings in line when it publishes results Monday, quarterly profit would be up 7.14%. Revenue would be up 115.19% from the same quarter last year. Vascular Biogenics's reported EPS has stacked up against analyst estimates in the past like this:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate -0.14 -0.17 -0.13 -0.14 EPS Actual -0.14 -0.15 -0.16 -0.14 Revenue Estimate 150.00 K 160.00 K 110.00 K 120.00 K Revenue Actual 158.00 K 366.00 K 126.00 K 79.00 K Stock Performance Shares of Vascular Biogenics were trading at $1.12 as of November 12. Over the last 52-week period, shares are down 2.99%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Vascular Biogenics is scheduled to hold the call at 08:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Sogou Earnings Preview * Earnings Preview: LiveXLive Media(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/13 15:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VBLT. Analyze the recent business situations of VASCULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VBLT stock price target is 3.850 with a high estimate of 5.00 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 2.41M
% Owned: 5.03%
Shares Outstanding: 47.90M
TypeInstitutionsShares
Increased
3
51.91K
New
8
-309.54K
Decreased
3
288.00K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Non-Executive Chairman/Independent Director
Bennett Shapiro
Chief Executive Officer/Director
Dror Harats
Chief Financial Officer/Secretary
Amos Ron
Vice President - Operations
Eyal Breitbart
Vice President
Erez Feige
Vice President
Tami Rachmilewitz
Vice President
Naamit Sher
General Counsel
Ayelet Horn
Non-Executive Independent Director
Ruth Alon
Non-Executive Independent Director
Ruth Arnon
Non-Executive Independent Director
Shmuel Ben Zvi
Non-Executive Independent Director
Ron Cohen
Non-Executive Independent Director
David Hastings
Non-Executive Independent Director
Susan Kelley
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VBLT
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBLT stock methods without spending real money on the virtual paper trading platform.